To be GMP or not to be– a radionuclide’s question
Abstract Background Radionuclides are the essential component of radiopharmaceuticals, their production needs to consider pharmaceutical regulations and guidelines, also for clinical research applications. Main body In this paper we reflect on the pharmaceutical regulatory landscape for radionuclide...
Saved in:
| Main Authors: | Clemens Decristoforo, Renata Mikolajczak, Clive Naidoo, Suzanne Lapi, Ferid Haddad, David Emmanuel Schmid, Lurdes Gano, Ulli Köster, Thierry Stora |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-07-01
|
| Series: | EJNMMI Radiopharmacy and Chemistry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41181-025-00369-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of a methodology for the analysis of radionuclide impurities in radiopharmaceuticals by gamma-ray spectrometry
by: Eduardo Bonfim De Paula, et al.
Published: (2017-11-01) -
RADIATION-HYGIENIC JUSTIFICATION OF OUTPATIENT RADIONUCLIDE THERAPY
by: B. Ja. Narkevich, et al.
Published: (2015-08-01) -
SOME ASPECTS OF CONDUCTING GMP INSPECTIONS IN RUSSIA
by: G. N. Gildeeva, et al.
Published: (2018-03-01) -
Regulation of Radiopharmaceutical Products
by: V. V. Kosenko, et al.
Published: (2022-12-01) -
Modern methods for radionuclide diagnosis of tumors and non-tumor pathologies of the brain
by: R. V. Zelchan, et al.
Published: (2022-01-01)